We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Basic View | Expanded View
 Showing 21-40 of 77 Articles
Comment & Response 
Willy Gomm, PhD; Britta Haenisch, PhD

In Reply First, we thank the authors of the letters for their interest and comments concerning our article.1

Comment & Response 
Helge L. Waldum, MD, PhD; Tom Christian Martinsen, MD, PhD

To the Editor We read with interest the article by Gomm and colleagues1 on an association between proton pump inhibitors and dementia. Concerning a possible mechanism, we would like to focus on our 2 previous studies showing that acidic gastric juice protected mice against prion infection.2...

Comment & Response 
Jineane V. Venci, PharmD, BCACP; Katherine W. Eisenberg, MD, PhD

To the Editor In their recent publication, Gomm et al1 found that regular proton pump inhibitor (PPI) use was associated with a 44% increased risk for dementia based on claims data from a large German health insurer. The authors concluded that avoidance of PPI use may prevent ...

Comment & Response 
William D. Freeman, MD

To the Editor I read with interest the article by Gomm et al1 investigating the association of proton pump inhibitors and dementia. The authors are to be commended for their large data set, analysis, and detailed proposed pathophysiologic mechanism by which this association might occur. However, 2 ...

Comment & Response 
Kanika Sharma, MD; Alireza Minagar, MD; Hai Sun, MD, PhD

To the Editor Gomm and colleagues1 examine the association of proton pump inhibitor (PPI) use with the risk for incidental dementia in the elderly population. Using longitudinal data derived from the Allgemeine Ortskrankenkassen database, the largest German health insurer, the authors conclude that patients receiving regular PPIs ...

Comment & Response 
Long Nguyen, MD, MS; Chin Hur, MD, MPH

To the Editor We read the article by Gomm et al1 with great interest as the long-term safety with prolonged proton pump inhibitor (PPI) use is of significant concern for both health care prescribers and patients. The investigators analyzed a prospective observational cohort of patients derived from ...

Babu G. Welch, MD; H. Hunt Batjer, MD

The evolution of the treatment of intracranial aneurysms has been fascinating to observe. Since the clipping of intracranial aneurysms began with Dr Walter Dandy in 1933, innovations in the intraoperative and postoperative management of aneurysms have made it possible for these lesions to be treated, rather than being ...

Michael K. Racke, MD; Jaime Imitola, MD

Multiple sclerosis (MS) has been characterized clinically as a disorder manifested by multiple episodes of neurologic dysfunction separated in space and time. Guidelines have been developed that use imaging and the revised McDonald Criteria for the diagnosis of MS.1 Magnetic resonance imaging (MRI) has been a useful ...

Rebecca F. Gottesman, MD, PhD

As acute management of intracerebral hemorrhage (ICH) has improved, more patients survive ICH but are left with significant deficits. In the past, primary evaluations of outcomes after ICH have focused on mortality1 and levels of functional dependence,2 with a relatively modest number of patients experiencing true ...

Original Investigation 
Alessandro Biffi, MD; Destiny Bailey, BS; Christopher D. Anderson, MD, MMSc; Alison M. Ayres, BA; Edip M. Gurol, MD; Steven M. Greenberg, MD, PhD; Jonathan Rosand, MD, MSc; Anand Viswanathan, MD, PhD
Includes: Supplemental Content

Importance  Patients who have experienced intracerebral hemorrhage (ICH) appear to develop cognitive impairment at high rates, both early after ICH and over the long term.

Objective  To identify and compare risk factors for early and delayed dementia after ICH.

Design, Setting, and Participants  A longitudinal ...

Editorial: Dementia After Intracerebral Hemorrhage; Rebecca F. Gottesman, MD, PhD
Original Investigation 
Allan MacKenzie-Graham, PhD; Florian Kurth, MD, PhD; Yuichiro Itoh, PhD; He-Jing Wang, MD; Michael J. Montag, MS; Robert Elashoff, PhD; Rhonda R. Voskuhl, MD

Importance  Multiple sclerosis (MS) is characterized by progressive gray matter (GM) atrophy that strongly correlates with clinical disability. However, whether localized GM atrophy correlates with specific disabilities in patients with MS remains unknown.

Objective  To understand the association between localized GM atrophy and clinical disability in ...

Editorial: Cortical Volume Loss and Neurologic Dysfunction in Multiple Sclerosis; Michael K. Racke, MD; Jaime Imitola, MD
Brian P. Walcott, MD; Christopher J. Stapleton, MD; Omar Choudhri, MD; Aman B. Patel, MD
Includes: Supplemental Content

Importance  Brain aneurysms have traditionally been treated with surgical clipping or endovascular coiling techniques. With these modalities, many large or complex aneurysms remain difficult to treat. A new option, flow diversion, is now available to treat aneurysms.

Objective  To summarize the clinical progression of flow diversion ...

Editorial: Consideration of Flow Diversion in Modern Cerebrovascular Neurosurgery; Babu G. Welch, MD; H. Hunt Batjer, MD
Comment & Response 
Josef Finsterer, MD, PhD; Sinda Zarrouk-Mahjoub, PhD

To the Editor With interest we read the article by Koenig et al1 about the management of strokelike episodes (SLEs) by early administration of the nitric oxide precursors l-arginine or citrulline. We have the following comments and concerns.

Comment & Response 
Mary Kay Koenig, MD

In Reply We thank Finsterer and Zarrouk-Mahjoub for their interest in our article1 and direct them to our introduction to address most of their concerns. They mention that there are examples in the literature where patients experiencing a strokelike episode completely recover. We agree with this statement. ...

Christina M. Marra, MD

This Editorial discusses the US Preventive Services Task Force recommendation statement on screening for syphilis infection in nonpregnant adults and adolescents.

Viewpoint  FREE
Carl A. Gold, MD, MS; S. Andrew Josephson, MD

This Viewpoint discusses challenges that the US health care system could face if the incidence of Guillain-Barré syndrome were to increase with the arrival of Zika.

Philip B. Gorelick, MD, MPH; Muhammad U. Farooq, MD

A recent major clinical advance in magnetic resonance imaging (MRI) of the brain is the development of paramagnetic-sensitive sequences such as T2-weighted gradient-recalled echo and susceptibility-weighted images for the detection of cerebral microbleeds (CMBs).1,2 On brain MRI, CMBs are small (≤5 to 10 mm in ...

Justin T. Jordan, MD

Immune-mediated therapies are unquestionably the most exciting wave of oncologic care in decades. For the first time in the history of multiple types of cancer, to our knowledge, investigators are contemplating the label of cure for certain patients. As has been seen with other forms of noncytotoxic chemotherapies ...

Original Investigation 
Saloua Akoudad, MD, PhD; Frank J. Wolters, MD; Anand Viswanathan, MD, PhD; Renée F. de Bruijn, MD, PhD; Aad van der Lugt, MD, PhD; Albert Hofman, MD, PhD; Peter J. Koudstaal, MD, PhD; M. Arfan Ikram, MD, PhD; Meike W. Vernooij, MD, PhD
Includes: Supplemental Content

Importance  Cerebral microbleeds are hypothesized downstream markers of brain damage caused by vascular and amyloid pathologic mechanisms. To date, whether their presence is associated with cognitive deterioration in the general population remains unclear.

Objective  To determine whether microbleeds, and more specifically microbleed count and location, are ...

Editorial: Cerebral Microbleeds, Cognition and Therapeutic Implications; Philip B. Gorelick, MD, MPH; Muhammad U. Farooq, MD
Original Investigation 
Tanya J. Williams, MD, PhD; David R. Benavides, MD, PhD; Kelly-Ann Patrice, MBBS; Josep O. Dalmau, MD, PhD; Alexandre Leon Ribeiro de Ávila, MD, PhD; Dung T. Le, MD; Evan J. Lipson, MD; John C. Probasco, MD; Ellen M. Mowry, MD, MCR
Includes: Supplemental Content

Importance  Paraneoplastic encephalitides usually precede a diagnosis of cancer and are often refractory to immunosuppressive therapy. Conversely, autoimmune encephalitides are reversible conditions that can occur in the presence or absence of cancer.

Objective  To report the induction of autoimmune encephalitis in 2 patients after treatment of ...

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts